BioStock: Respiratorius carries out directed share issue and initiates bridging study with VAL001

On Tuesday morning, Lund-based drug developer Respiratorius announced that it had carried out a directed share issue of 25 MSEK. The issue is intended to finance the bridging study with VAL001 that is planned in the preparatory work to take the candidate to phase III. BioStock contacted the company's CEO Johan Drott to find out more about what this means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/respiratorius-carries-out-directed-share-issue-and-initiates-bridging-study-with-val001/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se